On October 11, according to the latest announcement on the official website of the National Medical Products Administration (NMPA),Qilu Pharmaceutical (Hainan)According to the Chemical Drug Registration ClassificationCategory 4DeclaredCarfilzomib for InjectionApproved for marketing and deemed to have passed the evaluation. In the past three years, this product has performed remarkably in the global market, with annual sales exceeding 1 billion US dollars, demonstrating significant market potential.

Screenshot source: NMPA

CarfilzomibByProteolixThe company was the first to develop the drug, which then underwent two rounds of acquisitions: Onyx acquired it in 2009, and Amgen acquired Onyx in August 2013. In July 2012, the drug was first approved for marketing in the United States for patients who have received at leastBortezomibPatients with multiple myeloma treated with two regimens of immunomodulators, becoming the successorBortezomibThe second proteasome inhibitor to receive FDA approval. Currently,CarfilzomibIt has been launched in many countries around the world, with sales continuing to rise. Global sales broke through 1 billion US dollars in 2020, and according to the Maxia Medicine database, sales exceeded 1.5 billion US dollars in 2024.

In the Chinese market, this drug was approved for marketing in China in 2021 and was subsequently successfully included in the National Reimbursement Drug List (NRDL). After being incorporated into the NRDL, its market demonstrated rapid growth. In 2024, carfilzomib’s sales revenue in the all-terminal hospital market strongly exceeded 200 million yuan, with a year-on-year growth rate of 90.45%. Entering 2025, its growth momentum remains robust, with sales reaching 152 million yuan in just the first half of the year, representing a year-on-year increase of 39.13%, indicating significant market potential.